Elios Therapeutics Reports 24-Month Survival Data for Personalized Vaccine

Nov 21, 2019

|

NEW YORK – Elios Therapeutics reported 24-month survival data from a trial investigating its tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with advanced, resected melanoma.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Menu

Elios Therapeutics Reports 24-Month Survival Data for Personalized Vaccine

To read the full story....

Breaking News

Roche Ending Partnership With Syapse

AstraZeneca, Merck's Lynparza Approved in China for BRCA-Mutated Ovarian Cancer

Genentech Garners FDA Approval for Tecentriq in Front-Line Lung Cancer Regardless of PD-L1 Status

PGDx Gets IDE For Tissue NGS Test in Merck Immunotherapy Trial

FDA Approves Foundation Medicine CDx for Novartis Breast Cancer Drug Piqray

NantKwest Reports No Dose-Limiting Toxicities in Early Evaluation of Natural Killer Cell Therapy

What's Popular?

PGDx Gets IDE For Tissue NGS Test in Merck Immunotherapy Trial

AstraZeneca, Merck's Lynparza Approved in China for BRCA-Mutated Ovarian Cancer

Oncologists, Patient Groups Eagerly Await Access to KRAS Inhibitors Based on Promising Early Data

NantKwest Reports No Dose-Limiting Toxicities in Early Evaluation of Natural Killer Cell Therapy

Genentech Garners FDA Approval for Tecentriq in Front-Line Lung Cancer Regardless of PD-L1 Status

Sponsorships